CHD4

Across TCGA pan-cancer cohorts, CHD4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CHD4 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CHD4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHD4 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

OV, ESCA, and UCS are the cancer types where CHD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.335	0.847	<.001	36	view →
ESCA	OS	Median	III,IV	0.108	0.574	<.001	30	view →
UCS	DFS	Median	IV	0.132	0.718	.002	12	view →
LUAD	OS	Median	II,III,IV	0.004	0.751	<.001	12	view →
SKCM	OS	Median	III,IV	0.257	0.737	<.001	5	view →
BLCA	OS	Median	III,IV	0.894	0.559	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CHD4–OV (OS)

Open the OV breakdown →